News & Events:HOLX

--Leader in Women’s Health and Presenting Sponsor of Mary J. Blige’s “Good Morning Gorgeous” Tour Offers Fans a Chance to Win Tickets to Concerts Taking Place Across the Nation this Fall-- Hologic, Inc. (HOLX), a global leader in women’s health, and Grammy award-winning and Oscar-nominated artist, producer, and entrepreneur Mary J. Blige today announced the launch of the “Good Morning Gorgeous” sweeps...

Hologic, Inc. (HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic (HOLX). “We are pleased that the U.S. Court of Appeals has once again ruled in our favor.

CARLSBAD, Calif. Details about Active Motif's proprietary Cut&Tag-IT TM technology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit. About Active MotifActive Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com.

Pulled from Benzinga Pro data, Hologic posted Q3 earnings of $228.40 million, an increase from Q2 of 49.88%. Sales dropped to $1.00 billion, a 30.15% decrease between quarters. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

Hologic reported its Q3 earnings results on Wednesday, July 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Hologic beat estimated earnings by 33.8%, reporting an EPS of $0.95 versus an estimate of $0.71. Revenue was down $165.00 million from the same period last year.

– Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations –. – Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency –. – Company Again Increases Full-Year Revenue and EPS Guidance –. MARLBOROUGH, Mass.

  ** Equinor is projected to report earnings for its second quarter. ** Alkermes is estimated to report quarterly earnings at $0.01 per share on revenue of $269.00 million. ** Imperial Ptrl is estimated to report earnings for its second quarter. ** Stifel Financial is projected to report earnings for its second quarter.

  ** Equinor is projected to report earnings for its second quarter. ** Alkermes is estimated to report quarterly earnings at $0.01 per share on revenue of $269.00 million. ** Imperial Ptrl is estimated to report earnings for its second quarter. ** Stifel Financial is projected to report earnings for its second quarter.

B of A Securities upgraded the previous rating for Check Point Software Technologies Ltd from Underperform to Buy. According to Stifel, the prior rating for Franco-Nevada Corp was changed from Hold to Buy. According to Stifel, the prior rating for Xylem Inc was changed from Hold to Buy. According to HSBC, the prior rating for Chevron Corp was changed from Hold to Buy.

Within the last quarter, Hologic has observed the following analyst ratings: According to 5 analyst offering 12-month price targets in the last 3 months, Hologic has an average price target of $80.0 with a high of $85.00 and a low of $75.00. Below is a summary of how these 5 analysts rated Hologic over the past 3 months.

--Global Leader in Women's Health Highlights Importance of Timely and Accurate Diagnosis-- Hologic, Inc. (HOLX) will showcase their comprehensive portfolio of breast and skeletal health solutions at the annual European Congress of Radiology in Vienna, Austria from July 13-17.

--New assays for the Panther Fusion and Novodiag Systems further build on Hologic’s leading molecular scalable solutions offering to European customers-- Hologic, Inc. (HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere’s respiratory viral se...

Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes. Interested participants may listen to the call by dialing 289-0720 or +1 701-0160 and referencing access code 6025981.

Hologic Taking Action with 'Hey, U!' Campaign to Educate Women in Conjunction with Fibroid Awareness Month A new survey commissioned by Hologic, Inc. (HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

-- New quantitative assays for Epstein-Barr Virus and BK Virus expand Hologic’s Panther Fusion transplant pathogen monitoring menu -- Hologic, Inc. (HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.

Analysts have provided the following ratings for Hologic within the last quarter: These 6 analysts have an average price target of $80.0 versus the current price of Hologic at $78.765, implying upside. Below is a summary of how these 6 analysts rated Hologic over the past 3 months.

On CNBC's "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said Charles Schwab Corporation is trading at 14 times next year's earnings. Degas Wright of Decatur Capital Management cited Hologic, Inc. saying he likes the company for its "strong growth and diagnostics and imaging products." Check out other medical and tech stocks making big moves in the premarket.

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned.

Pulled from Benzinga Pro data, Hologic posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue